Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Binod Dhakal, Jesus G. Berdeja, Tara Gregory, Thomas Ly, Cara Bickers, Xingyue Zong, Lilly Wong, Jode P. Goodridge, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, John Byon, Rafat Abonour

Blood (2022) 140 (Supplement 1): 4586–4587.

https://doi.org/10.1182/blood-2022-166994

Published: 2022

Journal Articles

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Mark Juckett, Sham Mailankody, Alireza Eghtedar, Cara Bickers, Xingyue Zong, Lilly Wong, Thomas Ly, John Byon, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, Ravi Vij

Blood (2022) 140 (Supplement 1): 10327–10328.

https://doi.org/10.1182/blood-2022-166728

Published: 2022

Journal Articles

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Sham Mailankody, MBBS, Myo Htut, MD, Kelvin P. Lee, MD, William Bensinger, MD, Todd Devries, PhD, Julia Piasecki, BA, Safiyyah Ziyad, PhD, Michelle Blake, PhD, John Byon, MDPhD, Andrzej Jakubowiak, MD PhD

Blood (2018) 132 (Supplement 1): 957.

https://doi.org/10.1182/blood-2018-99-113548

Published: 2018

Journal Articles

Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Cherie Green, Mark Yan, Stefani Nalle, Connie Ma, Alberto Robert, Judy Zhong, Kartik Krishnan, Patrick Phuong, PharmD, John Byon, Paul Woodard, Michael J. Nemeth, PhD, Elizabeth A. Griffiths, MD, Joanne I. Adamkewicz, Jeffrey M. Venstrom, Monique Dail

Blood (2017) 130 (Supplement 1): 4241.

https://doi.org/10.1182/blood.V130.Suppl_1.4241.4241

Published: 2017

Journal Articles

Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML

Monique Dail, Long Yang, Cherie Green, Connie Ma, Alberto Robert, Edward E. Kadel, Harmut Koeppen, Joanne Adamkewicz, John Byon, Joseph Woodard, Scott J Rodig, Jeffrey M Venstrom

Blood (2016) 128 (22): 1340.

https://doi.org/10.1182/blood.V128.22.1340.1340

Published: 2016

Journal Articles

Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma

Mahesh Yadav, Cherie Green, Connie Ma, Alberto Robert, Andrew Glibicky, Rin Nakamura, Teiko Sumiyoshi, Ray Meng, Yu-Waye Chu, Jenny Wu, John Byon, Joseph Woodard, Joanne Adamkewicz, Jane Grogan, Jeffrey M. Venstrom

Blood (2016) 128 (22): 2102.

https://doi.org/10.1182/blood.V128.22.2102.2102

Published: 2016

Journal Articles

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brian G. Till, MD, Steven I. Park, MD, Leslie L. Popplewell, MD, Andre Goy, MD, Elicia Penuel, PhD, Jeffrey M Venstrom, MD, Bo Liu, Guenter Fingerle-Rowson, MD PhD, John Byon, MD PhD, Paul Woodard, MD, M. Lia Palomba, MD

Blood (2015) 126 (23): 5104.

https://doi.org/10.1182/blood.V126.23.5104.5104

Published: 2015

Journal Articles

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

Ekapun Karoopongse, MD, John Byon, MD, PhD, Cecilia Yeung, MD, H. Joachim Deeg, MD, A. Mario Q. Marcondes, MD, PhD

Blood (2013) 122 (21): 1543.

https://doi.org/10.1182/blood.V122.21.1543.1543

Published: 2013

Journal Articles

FLVCR Deletion Does Not Impact Normal Hematopoietic Stem Cell Function but Is Necessary for Erythroid and T-Cell Maturation and Enhances Platelet Formation

John Byon, MD, PhD, Jing Chen, MD, Raymond T Doty, PhD, Janis L. Abkowitz, MD

Blood (2011) 118 (21): 2363.

https://doi.org/10.1182/blood.V118.21.2363.2363

Published: 2011

NARROW

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML

Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

FLVCR Deletion Does Not Impact Normal Hematopoietic Stem Cell Function but Is Necessary for Erythroid and T-Cell Maturation and Enhances Platelet Formation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only